United Kingdom (UK)
Recombinant monoclonal antibody to MMAE. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 04CT2.2.3.
Alternative Name(s) of Target: Monomethylauristatin E; Vedotin; USAN; monomethyl auristatin F; NMAF; auristatins
Immunogen: The original antibody was generated by immunizing BALB/c mice with MMAE-cysteine-KLH conjugate in equal volume of complete Freund's adjuvant.
Specificity: This antibody binds auristatin (MMAE, MMAF) which is a cytotoxic drug (payload) employed in the ADC field. Monomethyl auristatin E (MMAE, vedotin) is a very potent antimitotic agent that inhibits cell division by blocking the polymerization of tubulin. The family of auristatins are synthetic analogues of the antineoplastic natural product Dolastatin 10, ultrapotent cytotoxic microtubule inhibitors that are clinically used as payloads in antibody-drug conjugates. As an antibody-drug conjugate or ADC, MMAE is linked to a monoclonal antibody (mAb) that recognizes a specific marker expression in cancer cells and directs MMAE to a specific, targeted cancer cell.
Application Notes: The binding activity of this antibody towards MMAE-BSA conjugate was determined using ELISA. This antibody is also capable of binding to MMAE-conjugated antibody drugs and can be used for their detection in cancer research (CN114181307).
Antibody first published in: PMID: